葵花药业
(002737)
| 流通市值：91.22亿 | | | 总市值：91.22亿 |
| 流通股本：5.84亿 | | | 总股本：5.84亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 663,495,324.67 | 3,377,047,677.27 | 2,966,906,461.88 | 2,527,602,096.82 |
| 营业收入 | 663,495,324.67 | 3,377,047,677.27 | 2,966,906,461.88 | 2,527,602,096.82 |
| 二、营业总成本 | 612,330,871.14 | 2,865,437,208.18 | 2,354,275,676.31 | 1,919,138,011.84 |
| 营业成本 | 416,109,372.38 | 1,860,974,575.18 | 1,417,182,527.64 | 1,119,651,646.08 |
| 税金及附加 | 10,660,668.02 | 49,356,549.45 | 38,708,788.97 | 30,209,135.09 |
| 销售费用 | 82,215,847.3 | 431,006,208.26 | 540,060,782.14 | 517,723,975.72 |
| 管理费用 | 84,457,759.04 | 423,069,390.92 | 300,622,453.51 | 221,082,583.85 |
| 研发费用 | 20,190,757.43 | 124,129,574.53 | 79,433,350.55 | 51,434,495.15 |
| 财务费用 | -1,303,533.03 | -23,099,090.16 | -21,732,226.5 | -20,963,824.05 |
| 其中:利息费用 | 112,062.84 | 3,562,424.06 | 1,619,717.18 | 354,115.8 |
| 其中:利息收入 | 2,008,095.81 | 27,277,742 | 24,133,291.74 | 21,712,149.32 |
| 加:公允价值变动收益 | -348,513.23 | -12,985,379.3 | -3,573,110.59 | -12,288,734.9 |
| 加:投资收益 | 2,905,256.09 | 24,931,696.6 | 12,785,310.25 | 9,230,674.13 |
| 资产处置收益 | -10 | -240,150.99 | -185,101.9 | 94.21 |
| 资产减值损失(新) | -1,143,003.3 | -56,930,045.1 | -3,649,650.6 | -992,192.51 |
| 信用减值损失(新) | -3,079,516.99 | -5,879,407.57 | -21,286,655.05 | -7,920,875.6 |
| 其他收益 | 23,207,252.3 | 175,736,197.02 | 144,473,067.26 | 40,619,319.45 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 72,705,918.4 | 636,243,379.75 | 741,194,644.94 | 637,112,369.76 |
| 加:营业外收入 | 56,755.06 | 7,159,700.78 | 5,742,043.3 | 4,481,272.2 |
| 减:营业外支出 | 2,574,897.3 | 8,915,551.98 | 2,570,616.22 | 1,392,382.4 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 70,187,776.16 | 634,487,528.55 | 744,366,072.02 | 640,201,259.56 |
| 减:所得税费用 | 11,346,391.34 | 131,756,020.25 | 138,852,550.27 | 123,917,307.96 |
| 六、净利润 | 58,841,384.82 | 502,731,508.3 | 605,513,521.75 | 516,283,951.6 |
| 持续经营净利润 | 58,841,384.82 | 502,731,508.3 | 605,513,521.75 | 516,283,951.6 |
| 归属于母公司股东的净利润 | 57,111,821.08 | 492,045,424.13 | 586,835,406.5 | 486,332,757.84 |
| 少数股东损益 | 1,729,563.74 | 10,686,084.17 | 18,678,115.25 | 29,951,193.76 |
| (一)基本每股收益 | 0.1 | 0.84 | 1 | 0.83 |
| (二)稀释每股收益 | 0.1 | 0.84 | 1 | 0.83 |
| 八、其他综合收益 | -13,366.08 | 122,718.96 | 120,556.8 | 17,035.2 |
| 归属于母公司股东的其他综合收益 | -9,356.26 | 85,903.27 | 84,389.76 | 11,924.64 |
| 九、综合收益总额 | 58,828,018.74 | 502,854,227.26 | 605,634,078.55 | 516,300,986.8 |
| 归属于母公司股东的综合收益总额 | 57,102,464.82 | 492,131,327.4 | 586,919,796.26 | 486,344,682.48 |
| 归属于少数股东的综合收益总额 | 1,725,553.92 | 10,722,899.86 | 18,714,282.29 | 29,956,304.32 |
| 公告日期 | 2025-04-25 | 2025-04-25 | 2024-10-29 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |